Cumulative HbA1c exposure as a CVD risk in patients with type 2 diabetes: A post hoc analysis of Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial
Primary result · Primary outcomeResult — go to the resultHazard ratio 1.32 95 % CI 1.22–1.43Authors' conclusion
Higher cumulative HbA1c exposure was significantly associated with an increased risk of the primary outcome, all-cause mortality and cardiovascular death among T2D patients. Patients with T2D should strive for stable glycemic control to reduce their risk of cardiovascular events, and that those with high baseline HbA1c may require more intensive therapy to achieve this goal.
Study context
- Population
- Patients with T2D in the ACCORD trial
- Participants
- 9,307 patients
- Comparison
- Per 1-SD increase in cumulative HbA1c exposure
- Primary endpoint
- Primary outcome (cardiovascular events)
Methodological detailsCumulative HbA1c exposure calculated as the area under the curve during exposure time
- Cumulative HbA1c exposure calculated as the area under the curve during exposure time
Primary result
Primary outcome
Hazard ratio
1.32
95 % CI 1.22–1.43
P < 0.001
Per 1-SD increase in cumulative HbA1c exposure
HR 1.32 (95 % CI 1.22–1.43); P < 0.001
Per 1-SD increase in cumulative HbA1c exposure, as printed
As reported in the abstract
Further findings
| Outcome | HR (95 % CI) | P value | |
|---|---|---|---|
| All-cause mortalityAdjusted for covariates | 1.33 (1.21–1.46) | P < 0.001 | |
| Cardiovascular deathAdjusted for covariates | 1.45 (1.27–1.67) | P < 0.001 | |
| 0.512Hazard ratio (log scale) |
Cross-tabulation: intensive-therapy group with high baseline HbA1c and cumulative HbA1c exposure
- Significantly higher risk of primary outcome, all-cause mortality and cardiovascular death
Original publication
Cumulative HbA1c exposure as a CVD risk in patients with type 2 diabetes: A post hoc analysis of ACCORD trial. Diabetes Res Clin Pract. Published 10 November 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →